Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for pulmonary hypertension after finding adverse health effects in patients trialing the drug. Shares fell 16% to $10.54.

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins,

Investing.com -- Shares of Keros Therapeutics (NASDAQ:KROS) tumbled 17% after the company announced a voluntary halt on all dosing in the TROPOS trial, which is evaluating cibotercept (KER-012) in patients with pulmonary arterial hypertension (PAH). The decision came as a result of new safety concerns related to pericardial effusion adverse events.

Keros Therapeutics has halted the dosing of its treatment for pulmonary hypertension due to adverse health effects discovered during trials. The clinical-stage biopharmaceutical company said Wednesday that it has voluntarily halted all dosing in the phase 2 Tropos trial for the drug cibotercept, which aims to treat pulmonary arterial hypertension.

Keros Therapeutics (KROS) announced that it has voluntarily halted all dosing in the TROPOS trial, a Phase 2 clinical trial of cibotercept in